Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
16.8M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
406K
-
Shares change
-
+72.9K
-
Total reported value, excl. options
-
$3.07M
-
Value change
-
+$531K
-
Number of buys
-
6
-
Number of sells
-
-5
-
Price
-
$7.60
Significant Holders of Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) as of Q1 2024
19 filings reported holding ELTX - Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q1 2024.
Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 406K shares
of 16.8M outstanding shares and own 2.42% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (216K shares), CM Management, LLC (75K shares), GEODE CAPITAL MANAGEMENT, LLC (47.7K shares), STATE STREET CORP (17.6K shares), MEYER HANDELMAN CO (13.9K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (12.5K shares), RENAISSANCE TECHNOLOGIES LLC (11.8K shares), CIBC Private Wealth Group, LLC (7K shares), Steward Partners Investment Advisory, LLC (1.55K shares), and BANK OF AMERICA CORP /DE/ (1.15K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.